Enanta Pharmaceuticals (ENTA) Income towards Parent Company (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Income towards Parent Company data on file, last reported at -$13.1 million in Q1 2026.

• Quarterly Income towards Parent Company rose 42.19% year-over-year to -$13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$62.0 million (up 35.71% YoY) and the FY2025 annual result came in at -$81.9 million, up 29.43% from the prior year.
• Income towards Parent Company slipped to -$13.1 million in Q1 2026, from -$11.9 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of -$11.9 million in Q4 2025 to a low of -$39.1 million in Q2 2023.
• A 5-year average of -$26.2 million and a median of -$26.3 million in 2022 frame the typical range for Income towards Parent Company.
• The widest YoY moves for Income towards Parent Company: up 67.83% in 2022, down 31.95% in 2022.
• Tracing ENTA's Income towards Parent Company over 5 years: stood at -$29.0 million in 2022, then decreased by 15.25% to -$33.4 million in 2023, then surged by 33.28% to -$22.3 million in 2024, then surged by 46.44% to -$11.9 million in 2025, then slipped by 9.66% to -$13.1 million in 2026.
• The last three Income towards Parent Company figures came in at -$13.1 million (Q1 2026), -$11.9 million (Q4 2025), and -$18.7 million (Q3 2025), per Business Quant data.